These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38636432)

  • 1. Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review.
    Xiao YQ; Long J; Zhang SS; Zhu YY; Gu SX
    Bioorg Chem; 2024 Jun; 147():107380. PubMed ID: 38636432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77.
    Jiang H; Li W; Zhou X; Zhang J; Li J
    Int J Biol Macromol; 2024 Sep; 276(Pt 1):133706. PubMed ID: 38981557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
    Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents.
    Zagórska A; Czopek A; Fryc M; Jończyk J
    Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
    Cannalire R; Cerchia C; Beccari AR; Di Leva FS; Summa V
    J Med Chem; 2022 Feb; 65(4):2716-2746. PubMed ID: 33186044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure-activity relationships.
    Kerti L; Frecer V
    Bioorg Med Chem; 2024 Nov; 113():117909. PubMed ID: 39288705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.
    Alhadrami HA; Sayed AM; Sharif AM; Azhar EI; Rateb ME
    Molecules; 2021 May; 26(9):. PubMed ID: 34062737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-chymotrypsin-like protease in SARS-CoV-2.
    Al Adem K; Ferreira JC; Villanueva AJ; Fadl S; El-Sadaany F; Masmoudi I; Gidiya Y; Gurudza T; Cardoso THS; Saksena NK; Rabeh WM
    Biosci Rep; 2024 Aug; 44(8):. PubMed ID: 39036877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions.
    Shawky AM; Almalki FA; Alzahrani HA; Abdalla AN; Youssif BGM; Ibrahim NA; Gamal M; El-Sherief HAM; Abdel-Fattah MM; Hefny AA; Abdelazeem AH; Gouda AM
    Eur J Med Chem; 2024 Nov; 277():116704. PubMed ID: 39121741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of highly potent SARS-CoV-2 M
    Chen W; Feng B; Han S; Wang P; Chen W; Zang Y; Li J; Hu Y
    Bioorg Med Chem Lett; 2022 Feb; 58():128526. PubMed ID: 34998903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on SARS-CoV-2 Main Protease Inhibitors.
    Gao K; Wang R; Chen J; Tepe JJ; Huang F; Wei GW
    J Med Chem; 2021 Dec; 64(23):16922-16955. PubMed ID: 34798775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor.
    Jiang Y; Wu Y; Wang J; Ma Y; Yu H; Wang Z
    Curr Med Chem; 2024; 31(38):6204-6226. PubMed ID: 38529602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential SARS-CoV-2 protease M
    Kouznetsova VL; Huang DZ; Tsigelny IF
    Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and characterization of naturally occurring covalent inhibitors of SARS-CoV-2 M
    Hu Q; Zhang Y; Chen P; Zhang Y; Zhu G; Liu W; Wang C; Zheng S; Shen N; Wang H; Huang P; Ge G
    Chin J Nat Med; 2024 Sep; 22(9):797-807. PubMed ID: 39326974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis of rosmarinic acid inhibitory mechanism on SARS-CoV-2 main protease.
    Li Q; Zhou X; Wang W; Xu Q; Wang Q; Li J
    Biochem Biophys Res Commun; 2024 Sep; 724():150230. PubMed ID: 38865813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease.
    Deshmukh MG; Ippolito JA; Zhang CH; Stone EA; Reilly RA; Miller SJ; Jorgensen WL; Anderson KS
    Structure; 2021 Aug; 29(8):823-833.e5. PubMed ID: 34161756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.
    Citarella A; Dimasi A; Moi D; Passarella D; Scala A; Piperno A; Micale N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.